#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	3870	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2545	452.0	0	.	n	.	0	C1450T	SNP	1450	1450	C	1926	1926	T	522	T	441	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	3870	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2545	452.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1660	1660	C	598	C,T	467,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	3870	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2545	452.0	0	HET	.	.	.	A69G	.	69	69	A	545	545	A	535	A,G	218,217	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6528	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3830	509.5	0	.	n	.	0	G1337A	SNP	1337	1337	G	1830	1830	A	492	A,C	400,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6528	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3830	509.5	0	.	n	.	0	T1971C	SNP	1971	1971	T	2464	2464	C	621	C,A,T	490,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6528	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3830	509.5	1	SNP	n	A2045G	0	.	.	2045	2045	A	2538	2538	A	651	A,C	515,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6528	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3830	509.5	1	SNP	n	C2597T	0	.	.	2597	2597	C	3090	3090	C	610	C,A	493,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_M_01364c	folP.WHO_M_01364c	1	1	539	572	folP	852	852	99.88	folP.l15.c4.ctg.1	1834	93.0	0	.	p	.	0	E151K	NONSYN	451	453	GAA	878	880	AAA	116;115;115	A,C;A;A	96,1;95;97	.	.
folP.WHO_M_01364c	folP.WHO_M_01364c	1	1	539	572	folP	852	852	99.88	folP.l15.c4.ctg.1	1834	93.0	1	SNP	p	R228S	1	.	.	682	684	AGC	1109	1111	AGC	135;135;135	A;G;C	103;109;107	folP.WHO_M_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1260	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3731	101.0	1	SNP	p	S91F	0	.	.	271	273	TCC	777	779	TCC	95;95;94	T;C,T;C	76;75,1;74	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1260	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3731	101.0	1	SNP	p	D95N	0	.	.	283	285	GAC	789	791	GAC	92;93;95	G;A;C	72;76;76	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1260	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3731	101.0	1	SNP	p	D95G	0	.	.	283	285	GAC	789	791	GAC	92;93;95	G;A;C	72;76;76	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	27	580	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1561	110.7	1	SNP	p	G45D	0	.	.	133	135	GGC	507	509	GGC	186;185;184	G;G,A;C	143;143,1;147	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	332	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c4.ctg.1	1373	72.5	0	.	n	.	0	A197.	DEL	197	197	A	704	704	A	148	A	120	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	1266	parC	2304	2304	99.91	parC.l6.c4.ctg.1	3325	113.8	1	SNP	p	D86N	0	.	.	256	258	GAC	682	684	GAC	140;139;140	G;A,T;C	110;101,1;112	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	1266	parC	2304	2304	99.91	parC.l6.c4.ctg.1	3325	113.8	1	SNP	p	S87I	0	.	.	259	261	AGT	685	687	AGT	139;139;139	A;G;T	105;110;109	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	1266	parC	2304	2304	99.91	parC.l6.c4.ctg.1	3325	113.8	1	SNP	p	S87W	0	.	.	259	261	AGT	685	687	AGT	139;139;139	A;G;T	105;110;109	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	1266	parC	2304	2304	99.91	parC.l6.c4.ctg.1	3325	113.8	1	SNP	p	S87R	0	.	.	259	261	AGT	685	687	AGT	139;139;139	A;G;T	105;110;109	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	1266	parC	2304	2304	99.91	parC.l6.c4.ctg.1	3325	113.8	1	SNP	p	S88P	0	.	.	262	264	TCC	688	690	TCC	138;139;139	T;C;C	108;105;111	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1248	parE	1986	1986	100.0	parE.l6.c17.ctg.1	2876	129.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1685	1687	GGC	150;149;150	G;G;C	121;121;119	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	1004	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2611	114.3	1	SNP	p	A311V	0	.	.	931	933	GCA	1378	1380	GCA	148;146;147	G,T;C,A;A	122,1;122,1;121	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	1004	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2611	114.3	1	SNP	p	I312M	0	.	.	934	936	ATC	1381	1383	ATC	147;147;148	A;T;C	125;121;126	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	1004	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2611	114.3	1	SNP	p	V316T	0	.	.	946	948	GTG	1393	1395	GTG	148;148;149	G;T;G	130;125;128	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	1004	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2611	114.3	1	SNP	p	V316P	0	.	.	946	948	GTG	1393	1395	GTG	148;148;149	G;T;G	130;125;128	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	1004	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2611	114.3	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1897	1899	ACC	117;117;117	A;C;C	87;93;88	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	1004	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2611	114.3	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1951	1953	GCG	112;113;112	G;C,G;G	85;80,2;86	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	1004	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2611	114.3	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1951	1953	GCG	112;113;112	G;C,G;G	85;80,2;86	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	1004	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2611	114.3	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2074	2076	GGC	119;119;119	G;G;C	96;96;97	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	1004	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2611	114.3	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2083	2085	GGC	121;121;120	G;G,A;C	94;93,1;99	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	1004	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2611	114.3	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2101	2103	CTG	120;120;120	C,G;T;G,A	95,1;93;96,1	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1466	ponA	2397	2397	100.0	ponA.l6.c17.ctg.1	3373	129.9	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1714	1716	CCG	106;106;107	C;C;G	82;87;87	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	676	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2106	96.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	748	748	C	118	C	101	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	80	porB1a	984	297	90.37	porB1a.l6.c17.ctg.1	1182	18.3	0	.	p	.	0	H217N	NONSYN	649	651	CAT	910	912	AAT	10;10;10	A;A;T	8;8;8	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	80	porB1a	984	297	90.37	porB1a.l6.c17.ctg.1	1182	18.3	0	.	p	.	0	D218N	NONSYN	652	654	GAT	913	915	AAT	10;10;10	A;A;T	8;8;8	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	80	porB1a	984	297	90.37	porB1a.l6.c17.ctg.1	1182	18.3	0	.	p	.	0	V226A	NONSYN	676	678	GTA	937	939	GCA	9;9;9	G;C;A	8;8;8	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	80	porB1a	984	297	90.37	porB1a.l6.c17.ctg.1	1182	18.3	0	.	p	.	0	.	MULTIPLE	700	702	ACT	960	962	GTA	8;8;8	G;T;A	7;7;6	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	80	porB1a	984	297	90.37	porB1a.l6.c17.ctg.1	1182	18.3	0	.	p	.	0	S236N	NONSYN	706	708	AGC	966	968	AAC	8;7;7	A;A;C	7;6;6	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	80	porB1a	984	297	90.37	porB1a.l6.c17.ctg.1	1182	18.3	0	.	p	.	0	.	MULTIPLE	709	711	AAC	970	974	TGGCG	7;7;7;7;7	T;G;G;C;G	5;6;6;6;6	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	80	porB1a	984	297	90.37	porB1a.l6.c17.ctg.1	1182	18.3	0	.	p	.	0	D238A	NONSYN	712	714	GAT	976	978	GCT	7;7;7	G;C;T	6;6;6	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	80	porB1a	984	297	90.37	porB1a.l6.c17.ctg.1	1182	18.3	0	.	p	.	0	V258L	NONSYN	772	774	GTA	1036	1038	TTA	8;8;8	T;T;A	6;6;6	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	80	porB1a	984	297	90.37	porB1a.l6.c17.ctg.1	1182	18.3	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	1081	1083	CAT	9;9;9	C;A;T	6;6;6	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	80	porB1a	984	297	90.37	porB1a.l6.c17.ctg.1	1182	18.3	0	.	p	.	0	D274S	NONSYN	820	822	GAT	1084	1086	AGT	9;9;9	A;G;T	6;6;6	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	80	porB1a	984	297	90.37	porB1a.l6.c17.ctg.1	1182	18.3	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	1093	1095	TAC	9;9;9	T;A;C	6;6;6	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	738	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1929	113.9	0	.	p	.	0	N38E	NONSYN	112	114	AAT	581	583	GAA	140;141;141	G,T;A,C;A,C	104,1;105,1;106,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	738	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1929	113.9	0	.	p	.	0	N134D	NONSYN	400	402	AAT	869	871	GAT	145;146;146	G;A,C;T	119;119,1;119	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	738	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1929	113.9	0	.	p	.	0	P175S	NONSYN	523	525	CCA	992	994	TCA	152;152;152	T,G,C;C;A,C	115,1,1;123;117,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	738	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1929	113.9	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1121	1123	GTC	162;162;163	G;T;C,A	132;132;134,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	738	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1929	113.9	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1451	1453	GCA	165;165;165	G;C;A	128;133;130	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	738	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1929	113.9	1	SNP	p	G120K	1	.	.	358	360	AAG	827	829	AAG	151;152;152	A;A;G	120;120;126	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	738	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1929	113.9	1	SNP	p	A121D	1	.	.	361	363	GAC	830	832	GAC	151;150;150	G;A;C,A	124;124;127,1	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	738	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1929	113.9	1	SNP	p	D121N	0	.	.	361	363	GAC	830	832	GAC	151;150;150	G;A;C,A	124;124;127,1	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	2622	rpoB	4179	4179	99.98	rpoB.l6.c17.ctg.1	5160	151.9	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2160	2162	AAT	134;133;133	A;A;T,G	112;105;104,1	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	388	rpsJ	312	312	100.0	rpsJ.l6.c17.ctg.1	1299	89.2	1	SNP	p	V57M	1	.	.	169	171	ATG	685	687	ATG	168;169;171	A;T;G	134;133;133	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
